Liver Resection (Hepatectomy) — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Liver resection (hepatectomy) is a major surgical procedure that removes part or all of the liver to excise malignant or benign hepatic pathology. It is the most effective and potentially curative treatment for a range of hepatic conditions including primary liver tumours (hepatocellular carcinoma and intrahepatic cholangiocarcinoma), secondary liver tumours (colorectal liver metastases — the most common indication in Western practice), gallbladder cancer, and large or complex benign lesions (hepatic adenoma at risk of rupture, large symptomatic haemangiomas). The liver is unique among solid organs in its remarkable regenerative capacity: after resection of up to 70–75% of the liver volume in a healthy liver, the remnant undergoes compensatory regeneration to restore approximately 80% of the original liver volume within 6–8 weeks via hepatocyte proliferation driven by growth factors including hepatocyte growth factor (HGF) and transforming growth factor-alpha (TGF-α). This regenerative capacity makes major hepatectomies — including right hepatectomy (removing segments 5–8, approximately 60% of liver volume) and extended right hepatectomy (segments 4–8, up to 80% of volume) — biologically feasible when the future liver remnant (FLR) is sufficient. Anatomical resections follow the Couinaud segmental anatomy of the liver — eight functionally independent segments each with their own vascular inflow, outflow, and biliary drainage — allowing precise, anatomically guided parenchymal resections that minimise devascularisation of adjacent normal tissue. Liver resection is performed at specialist hepatobiliary surgical centres by hepatobiliary surgeons working within multidisciplinary oncology teams.

Patient selection for liver resection requires a comprehensive assessment balancing the extent of disease, potential for complete (R0) resection, adequacy of the future liver remnant, and the patient's overall fitness and underlying liver health. Primary indications include: hepatocellular carcinoma (HCC) in patients with adequate liver functional reserve — BCLC stage 0 and A tumours up to 3 cm in non-cirrhotic livers or compensated Child-Pugh A cirrhosis (where liver transplantation may also be an option); colorectal cancer liver metastases, where the liver is the sole or dominant site of disease and all lesions are technically resectable with a sufficient FLR — resectability has expanded from a rigid 4-lesion cut-off to a biological and technical assessment, and bilateral multifocal disease may be resectable with two-stage hepatectomy; intrahepatic cholangiocarcinoma; gallbladder cancer involving the liver bed; large hepatic adenomas (over 5 cm) with risk of haemorrhage; and large symptomatic haemangiomas not amenable to observation. Absolute contraindications include: insufficient future liver remnant volume (FLR below 20–30% in normal liver, below 40% in cirrhotic or chemotherapy-damaged liver) without portal vein embolisation pre-treatment; extrahepatic metastatic disease precluding curative intent (with some exceptions in colorectal cancer where limited extrahepatic disease is still resectable); Child-Pugh B or C cirrhosis with decompensated liver function; and unresectable vascular encasement preventing R0 margins. Portal vein embolisation (PVE) of the future-remnant-opposing portal territory, performed 4–6 weeks before resection, induces compensatory hypertrophy of the future remnant to a safe volume. Future liver remnant volumetry by CT is essential in all planned major resections.

Under general anaesthesia, the abdomen is opened via a right subcostal (Kocher) incision, bilateral subcostal incision (chevron), or midline incision depending on the planned resection extent and body habitus. Laparoscopic liver resection — used for lesions in favourable locations (segments 2, 3, 6) and for anatomical left lateral hepatectomy — achieves equivalent oncological outcomes with significantly reduced blood loss, shorter hospital stay, and faster recovery compared with open surgery at experienced centres. Intraoperative ultrasound (IOUS) is a critical tool, performed routinely at the start of each operation to confirm lesion number, define margins from major vessels, and identify any additional lesions not visible on preoperative imaging. The extent of resection is planned to achieve a minimum 1 cm resection margin from the tumour surface (R0 resection) where anatomically possible. The hepatic pedicle (portal vein, hepatic artery, bile duct) to the lobe or segment to be removed is controlled with vascular clamps or divided between clips and sutures. The Pringle manoeuvre — temporary clamping of the hepatoduodenal ligament to interrupt all hepatic inflow — is applied intermittently during parenchymal transection to control bleeding, with most surgeons using 15-minute clamp cycles with 5-minute reperfusion intervals. Parenchymal transection uses an ultrasonic dissector (CUSA), waterjet dissector, or bipolar electrocautery to selectively divide hepatocytes while identifying and securing intrahepatic vessels and biliary radicles with clips, sutures, or stapler. Hepatic vein control may require total vascular exclusion (simultaneous Pringle and hepatic vein clamping) for posterior segment or vein-adjacent tumours. After specimen removal, the cut liver surface is inspected for bile leaks (the table is tilted to test), haemostasis is secured, and a fibrin sealant may be applied. An abdominal drain is placed near the cut surface. Total operative time is typically 4–6 hours for major resections.

Liver resection offers the only realistic prospect of long-term cure or prolonged survival for patients with primary and secondary liver tumours. For colorectal liver metastases — the most common indication in Western practice — complete resection (R0) achieves 5-year overall survival of 30–50% in current series, representing a dramatic improvement over palliative chemotherapy alone (median survival 18–30 months). With modern chemotherapy regimens (FOLFOX, FOLFIRI with bevacizumab or cetuximab), an increasing proportion of initially unresectable liver metastases become resectable after downstaging chemotherapy — a strategy that extends surgical eligibility to an additional 15–30% of patients. For hepatocellular carcinoma in non-cirrhotic livers, 5-year overall survival after complete resection reaches 50–70%. For hepatocellular carcinoma in well-compensated (Child-Pugh A) cirrhosis with a single tumour under 3 cm, 5-year survival reaches 40–60%, though recurrence rates remain high due to the underlying cirrhotic field defect. Laparoscopic liver resection at specialist centres achieves equivalent oncological outcomes with significantly reduced intraoperative blood loss, lower transfusion requirement, shorter hospital stay (3–5 days vs 7–10 days), and faster return to adjuvant chemotherapy — all clinically meaningful advantages. The liver's regenerative capacity ensures that hepatic function is fully restored in the vast majority of patients within 6–8 weeks, allowing adjuvant therapy on schedule.

Liver resection at specialist hepatobiliary centres carries a 30-day mortality of under 3% for elective resections in non-cirrhotic patients — a dramatic improvement from historical mortality exceeding 10% two decades ago, attributable to improved patient selection, operative technique, and perioperative care. Post-hepatectomy liver failure (PHLF) — the development of impaired synthetic function (hyperbilirubinaemia, coagulopathy) in the remnant liver — occurs in 3–8% of major resections and is the primary cause of perioperative mortality; risk is elevated by pre-existing cirrhosis, chemotherapy-induced liver parenchymal damage (sinusoidal obstruction syndrome from oxaliplatin-based chemotherapy, steatohepatitis from irinotecan), and insufficient remnant volume. Bile leak from the liver cut surface or an inadvertently injured biliary radicle occurs in 5–10% and is managed by extended drain drainage and ERCP (endoscopic retrograde cholangiopancreatography) with biliary stenting in most cases; surgical re-exploration is rarely required. Haemorrhage requiring blood transfusion occurs in 10–20% of open resections (lower in laparoscopic); cell salvage and antifibrinolytic agents (tranexamic acid) reduce transfusion requirements. Intraabdominal infection and abscess formation occur in 3–7%, particularly in diabetic patients or those with bile leaks, and are managed with CT-guided percutaneous drainage. Venous thromboembolism risk is elevated in oncological liver surgery and requires pharmacological prophylaxis. Portal hypertension in cirrhotic patients may cause post-resection ascites. Mortality risk is higher in cirrhotic patients (Child-Pugh A: 3–5%), bilateral resections, and repeat hepatectomy for recurrence.

Following major liver resection, patients spend 24–48 hours in a high-dependency unit (HDU) or intensive care unit for monitoring of haemodynamics, fluid balance, liver function, and coagulation. Daily post-operative liver function tests — bilirubin, ALT, prothrombin time — track hepatic regeneration and identify early PHLF. Diet progresses from clear fluids on day 1 to a full diet by day 3–4 as bowel function returns. The abdominal drain is removed when output is serous and under 100 mL per day, typically by day 3–5. Discharge is usually at 5–7 days for open surgery and 3–5 days for laparoscopic resection. Wound care involves keeping the incision dry for 2 weeks; staples or clips are removed at 10–14 days in clinic. Heavy lifting (over 3–4 kg) is avoided for 6 weeks while the abdominal wall muscles and fascial closure consolidate. Light walking resumes from day 1; return to driving at 4–6 weeks; return to light desk work at 4–6 weeks and physical work at 8–12 weeks. Adjuvant chemotherapy — typically FOLFOX for colorectal liver metastases — commences 4–6 weeks post-operatively once liver function has normalised. Surveillance imaging (CT or MRI of chest, abdomen, and pelvis) is performed at 3-monthly intervals for the first 2 years, then 6-monthly to 5 years, as most recurrences occur within the first 2 years. Repeat hepatectomy for isolated hepatic recurrence in fit patients extends survival and should be considered at specialist centres. Serum CEA (for colorectal cancer) and AFP (for HCC) are monitored at each follow-up visit.